DandiCure

DandiCure is a South Korea-based private biotech company focused on early-stage drug discovery in oncology and other serious diseases. The company appears best known for PROTAC-based targeted protein degradation programs, including a preclinical Polo-like kinase 1 degrader for non-small cell lung cancer, and it has also been associated with peptide-related therapeutic work and peptide synthesis support. Publicly available evidence indicates a strategic relationship with Icure, which has described DandiCure as a subsidiary involved in developing a new drug based on PROTAC technology. The company remains preclinical, with limited public disclosure on its full pipeline, financing, and corporate profile. Overall, DandiCure looks like a small discovery-stage biotech centered on degraders and peptide-enabled therapeutic research.